Zymogen Activating Peptides Modulate HGF Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to activating hepatocyte growth factor (HGF) are limited by weak binding affinity of activator peptides, which hampers their therapeutic potential in stimulating tissue repair and wound healing, particularly in conditions like liver cirrhosis and pulmonary fibrosis where normal proteolytic activation of HGF is impaired.
Innovation Solution
Development of zymogen activating peptides (ZAPs) that interact with the β-chain domain of pro-HGF, specifically designed to modulate the activation of the Met receptor tyrosine kinase pathway by binding to the activation pocket of HGF, thereby enhancing its signaling activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional activator peptides are used to activate HGF, then HGF signaling can be stimulated, but the binding affinity is weak which limits therapeutic potential
Solution Approach 1:
The patent modifies the amino acid sequence of activator peptides by introducing specific mutations (e.g., changing residues at positions 3-6) to optimize binding affinity parameters. The consensus sequence pattern (X1-X2-X3-X4 where X1 is hydrophobic, X2 is aromatic/hydrophobic, X3 is polar, X4 is hydrophobic) represents parameter optimization to achieve high-affinity binding to the HGF activation pocket.
Solution Approach 2:
The patent creates synthetic peptide sequences that copy and adapt the binding motif from natural activators. The designed ZAP sequences replicate the functional characteristics of natural activator peptides while optimizing for affinity through systematic sequence design based on the identified consensus pattern.
2Reliability
If proteolytic cleavage is used to activate HGF, then active HGF is generated, but this process is impaired in conditions like liver cirrhosis and pulmonary fibrosis
Solution Approach 1:
The patent introduces ZAP peptides as intermediary molecules that mediate activation of HGF without requiring proteolytic cleavage. These peptides bind to the activation pocket of pro-HGF and stabilize the active conformation, serving as a non-proteolytic intermediary that bypasses the impaired cleavage mechanism in fibrotic conditions.
Solution Approach 2:
The patent replaces the proteolytic (enzymatic) activation mechanism with a direct allosteric activation mechanism. Instead of using proteases to cleave pro-HGF, the ZAP peptides directly bind to and activate the HGF protein through conformational stabilization, substituting a chemical/proteolytic mechanism with a molecular binding mechanism.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ZAPs demonstrate improved binding affinity and efficacy in activating HGF signaling, potentially offering a novel therapeutic approach for tissue repair and regeneration by enhancing the conversion of pro-HGF into its active form, even in conditions where normal proteolytic activation is compromised.
Implementation Method 1
allosteric activators that reversibly convert available pro-HGF into an active form, capable of Met signaling
Implementation Method 2
proteolytic cleavage at the Arg494-Val495 peptide bond results in a two-chain form
Data Source
AI summary
Provided herein are zymogen activating molecules such as zymogen activating peptides, and methods of identifying and using these zymogen activating molecules such as zymogen activating peptides.